Investigating how a specific enzyme affects cell metabolism and inflammation in acute lung injury.
Mitochondrial deubiquitinase USP30 regulates cell metabolism-mediated miRNA biogenesis and microvascular inflammation
This study is looking at how a specific enzyme called USP30 affects cell health and inflammation in serious conditions like ARDS and sepsis, and it hopes to find new ways to help improve blood vessel function and develop better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11048304 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the enzyme USP30 in regulating cell metabolism and inflammation, particularly in conditions like acute respiratory distress syndrome (ARDS) and sepsis. The study aims to explore how inhibiting USP30 can improve the function of microvascular endothelial cells, which are crucial for maintaining blood vessel integrity. By examining the molecular pathways involved, including the production of certain microRNAs, the research seeks to identify new therapeutic strategies for treating these life-threatening conditions. Patients may benefit from potential new treatments that target these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing acute respiratory distress syndrome or sepsis, particularly those caused by bacterial or viral infections.
Not a fit: Patients with chronic inflammatory diseases or those not experiencing acute respiratory distress may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce mortality and improve outcomes for patients suffering from acute inflammatory diseases like ARDS and sepsis.
How similar studies have performed: While the specific approach of targeting USP30 in microvascular inflammation is novel, similar research has shown promise in targeting metabolic pathways for treating acute inflammatory conditions.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Zhao, Yutong — Ohio State University
- Study coordinator: Zhao, Yutong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.